A Guth Labs publication ↗
Back to News

Orakl raises $34 million for AI cancer-drug prediction, not a replacement for clinical trials

Orakl raises $34 million for AI cancer-drug prediction, not a replacement for clinical trials

Orakl Oncology has announced a $34million Series A co-led by Norrsken VC and Singular. The November12 financing backs an AI-and-biology approach to deciding which cancer drugs merit further development. The amount and round are corroborated by the readable opening of Sifted’s report; the rest of that article was inaccessible behind its subscription presentation.

The phrase “virtual patients” needs unpacking. Investor Norrsken describes laboratory-grown patient tumours linked to clinical histories and biological information, not simply synthetic people generated by a chatbot. The investment announcement says the financing brings total funding to $50million and supports expansion of the dataset and AI research team.

Participating investor InfraVia describes plans to broaden work beyond colorectal and pancreatic cancer into lung and gastric cancer, alongside new US and UK teams. These are intended uses of capital, not completed deployments.

Both investors promote a 90% clinical-trial-outcome prediction figure. That is an attributed company/investor claim, not an independently validated clinical result in this coverage. The accessed announcements do not establish enough evaluation detail here to judge generalisation, sample size or performance on genuinely unseen programmes. A reported commercial pipeline likewise should not be counted as signed customers.

Guth analysis

The interesting AI story is the combination of models with expensive-to-create experimental evidence. Better predictions could help prioritise drug programmes, but funding does not establish patient benefit, regulatory acceptance or a substitute for trials. The next meaningful update would be inspectable prospective validation with denominators and clear definitions of success, rather than another isolated accuracy percentage.

Dates, sourcing and revision record

Actual announcement and all three cited source publication dates: November12,2026. Exact announcement time and financing closing date unknown. First coverage: November13,2026,02:53UTC / November12,18:53PST. Primary evidence: directly read Norrsken and InfraVia investor announcements, interested parties, not independent validation. Independent evidence: readable Sifted headline, deck and opening only, confirming round and amount. No additional background sources used. No patient data accessed; this is not a medical recommendation.

Sources and citations

Revision history

Published .